CD7 and acute lymphoblastic leukemia: These donor-derived fratricide-resistant CD7 CAR-T cells showed efficient antitumor activity in patients with R/R T-ALL, and 90% (n = 18) of patients achieved CR in their phase I clinical trial (NCT04689659).